文献速递慢性肾脏病肾小球疾病

托伐普坦对ADPKD患者肾功能与肾脏体积的长期影响

The long-term effect of tolvaptan treatment on kidney function and volume in patients with ADPKD.
PubMed 文献 · Nephrol Dial Transplant · 2025-01-01

该研究汇总DIPAK前瞻队列与OBSERVA回顾队列共615例ADPKD患者,其中105例接受托伐普坦治疗,匹配后92对分析显示托伐普坦使慢性期eGFR下降减缓14.0%,但长期总肾脏体积增长无显著变化。

要点

  • 托伐普坦使ADPKD患者慢性期eGFR下降减缓14.0%。
  • 长期托伐普坦治疗未显著改变总肾脏体积增长速度。
  • 平均渗透压摄入较高的患者托伐普坦疗效更明显。

核心结论

  • 真实世界数据显示长期托伐普坦可减缓ADPKD患者肾功能下降,但似乎不影响肾脏体积增长。

研究设计与样本

  • 汇总DIPAK前瞻队列与OBSERVA回顾队列数据,共615例ADPKD患者,105例接受托伐普坦治疗。
  • 匹配后92对患者进行对比分析,平均治疗时长6.1±4.7年。

主要发现

  • 亚组分析显示平均渗透压摄入较高的患者托伐普坦治疗效果更大。

临床怎么用

  • 可考虑对ADPKD患者长期使用托伐普坦以延缓肾功能下降,但不应期望其缩小或显著控制肾脏体积增长。

局限性

  • 真实世界观察性研究,托伐普坦组样本量较小(105例),匹配后仅92对。
  • 治疗时长范围宽(0.8至15.9年),可能存在残余混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND HYPOTHESIS: The only therapy to ameliorate disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD) is tolvaptan, a vasopressin V2 receptor antagonist. Real-life data on long-term tolvaptan treatment are sparse and limited by restricted follow-up, small patient groups or lack of a control group. We studied the long-term effect of tolvaptan on kidney function and kidney growth in real-life patients and controls. Moreover, we investigated determinants of long-term treatment efficacy. METHODS: Data from the prospective DIPAK cohort and retrospective OBSERVA cohort were pooled. estimated glomerular filtration rate (eGFR) was measured at least yearly and total kidney volume (TKV) at least every 3 years. Treatment effects from the start to 6 weeks after initiation of tolvaptan were analyzed as "acute slope." After this, endpoints were analyzed as "chronic slope." As a control group, we included all patients who were not treated with tolvaptan, assessing change in endpoints before and during theoretical treatment (based on the average time of tolvaptan initiation in tolvaptan-treated patients). RESULTS: A total of 615 patients (48 ± 12 years, 58.2% female) were included in the full analysis, of which 105 (17.1%) were treated with tolvaptan. The average duration of treatment was 6.1 ± 4.7 years (range 0.8 to 15.9). After matching, two groups of 92 patients remained for matched analysis. In this analysis, tolvaptan reduced eGFR decline during chronic slope by 14.0% (-4.36 to -3.75 mL/min/1.73 m2/year, P = .03), versus a decrease of 1.0% (-4.16 to -4.12 mL/min/1.73 m2/year, P = .9) in the control group. Long-term TKV growth did not significantly change during tolvaptan treatment (5.05 to 5.59%/year P = .6). In subgroup analyses, patients with a higher mean osmolar intake had a larger treatment effect of tolvaptan. CONCLUSION: In this study, with real-life patient data, long-term follow-up and a well-matched control group, we found that tolvaptan attenuated long-term kidney function decline but seemed not to influence kidney growth.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Geertsema P, Bais T, Kuiken V, et al. The long-term effect of tolvaptan treatment on kidney function and volume in patients with ADPKD. Nephrol Dial Transplant. 2025. PMID: 40052348. doi:10.1093/ndt/gfaf048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。